NCT06621563View on ClinicalTrials.gov

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

December 14, 2024

Primary Completion Date

March 30, 2026

Study Completion Date

December 1, 2026

Conditions
Solid TumorsNon-Small Cell Lung CancerColorectal Cancer
Interventions
DRUG

HS-20117 combined HS-20093

HS-20117 + HS-20093

DRUG

HS-20117 combined Platinum-containing chemotherapy

HS-20117 + cisplatin/carboplatin + pemetrexed

DRUG

HS-20117 combined HS-20093 and 5-FU

HS-20117 + HS-20093 + 5-FU

DRUG

HS-20117+CAPEOX

CAPOEX: Oxaliplatin+Capecitabine

DRUG

HS-20117+FOLFIRI

FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU

DRUG

HS-20117+mFOLFOX6

mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY